264 related articles for article (PubMed ID: 24982438)
1. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
[TBL] [Abstract][Full Text] [Related]
2. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
3. TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using
Minnix M; Li L; Yazaki PJ; Miller AD; Chea J; Poku E; Liu A; Wong JYC; Rockne RC; Colcher D; Shively JE
J Nucl Med; 2021 Jan; 62(1):55-61. PubMed ID: 32620701
[TBL] [Abstract][Full Text] [Related]
4. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
[TBL] [Abstract][Full Text] [Related]
6.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
7. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
9. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
Dahle J; Borrebaek J; Melhus KB; Bruland OS; Salberg G; Olsen DR; Larsen RH
Nucl Med Biol; 2006 Feb; 33(2):271-9. PubMed ID: 16546683
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
11. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 225Ac radioimmunopharmaceuticals.
McDevitt MR; Ma D; Simon J; Frank RK; Scheinberg DA
Appl Radiat Isot; 2002 Dec; 57(6):841-7. PubMed ID: 12406626
[TBL] [Abstract][Full Text] [Related]
13. Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.
Behling K; Maguire WF; López Puebla JC; Sprinkle SR; Ruggiero A; O'Donoghue J; Gutin PH; Scheinberg DA; McDevitt MR
J Nucl Med; 2016 Oct; 57(10):1576-1582. PubMed ID: 27127217
[TBL] [Abstract][Full Text] [Related]
14. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
15. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
16. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.
Chang MY; Seideman J; Sofou S
Bioconjug Chem; 2008 Jun; 19(6):1274-82. PubMed ID: 18505278
[TBL] [Abstract][Full Text] [Related]
17. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
18. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
19. Tumor therapy with targeted atomic nanogenerators.
McDevitt MR; Ma D; Lai LT; Simon J; Borchardt P; Frank RK; Wu K; Pellegrini V; Curcio MJ; Miederer M; Bander NH; Scheinberg DA
Science; 2001 Nov; 294(5546):1537-40. PubMed ID: 11711678
[TBL] [Abstract][Full Text] [Related]
20. Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S53-S57. PubMed ID: 31253514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]